Currently out of the existing stock ratings of Julian Harrison, 80 are a BUY (88.89%), 10 are a HOLD (11.11%).

Julian Harrison

Work Performance Price Targets & Ratings Chart

Analyst Julian Harrison, currently employed at BTIG, carries an average stock price target met ratio of 43.27% that have a potential upside of 62.91% achieved within 184 days.

Julian Harrison’s has documented 169 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on TBPH, Theravance Biopharma at 20-Mar-2026.

Wall Street Analyst Julian Harrison

Analyst best performing recommendations are on AVTE (AEROVATE THERAPEUTICS).
The best stock recommendation documented was for AVTE (AEROVATE THERAPEUTICS) at 12/6/2022. The price target of $27 was fulfilled within 6 days with a profit of $8.97 (49.75%) receiving and performance score of 82.92.

Average potential price target upside

of $32.25 (40.59%) on RXDX (PROMETHEUS BIOSCIENCES).
of $21.3 (102.78%) on PTGX (PROTAGONIST THERAPEUTICS).
of $15.28 (172.25%) on LQDA (LIQUIDIA TECHNOLOGIES).

PTGX Protagonist Therapeutics LQDA Liquidia Technologies AVTE Aerovate Therapeutics RXDX Prometheus Biosciences KROS Keros Therapeutics ACRS Aclaris Therapeutics AXLA Axcella Health VKTX Viking Therapeutics MORF Morphic CBAY Cymabay Therapeu MLTX MoonLake Immunotherapeutics ANAB AnaptysBio OTLK OUTLOOK THERAPEUTICS INC RZLT Rezolute VRDN Viridian Therapeutics TBPH Theravance Biopharma AKBA Akebia Ther ARDX Ardelyx CGEM Cullinan Oncology LLC NKTR Nektar Therapeutics RANI Rani Therapeutics Holdings

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Geoff Meacham (CITI)